Inclusion Criteria:

- Patients who have chronic cancer pain, and who have successfully completed the OROS
hydromorphone SR (slow release) study, DO-118

- Patients must have been in dose-stable pain control in the last two days of the slow
release phase of the study

- Patients who require at least 8mg of OROS hydromorphone slow release every 24 hours
for the management of chronic cancer pain

Exclusion Criteria:

- Pain which is not considered to be potentially responsive to opioids

- Gastrointestinal disease of sufficient severity to be likely to interfere with oral
analgesia including: dysphagia, vomiting, no bowel movement or bowel obstruction due
to impaction within the 5 days prior to the start of the trial, severe gut narrowing
that may affect the absorption or transit of orally administered drugs, particularly
the insoluble OROS outer coating

- Any patient in whom the risks of treatment with hydromorphone outweigh the potential
benefits. Such risk categories include: raised intracranial pressure, hypotension,
hypothyroidism, asthma, reduced respiratory reserve, prostatic hypertrophy, hepatic
impairment, renal impairment, elderly and debilitated, convulsive disorders and
Addison's disease